Adaptive Zika Virus Vaccine for Specialized Environments

This inventive concept adapts the recombinant measles virus expressing Zika virus prM and E proteins for specific, high-stakes environments, such as high-security facilities, disaster relief settings, extreme weather conditions, and immunocompromised populations.

The original patent provided a recombinant measles virus expressing Zika virus prM and E proteins as a vaccine candidate. However, this vaccine may not be suitable for specific, high-stakes environments that require tailored solutions. This inventive concept addresses these limitations by adapting the vaccine for these specialized environments, ensuring effective protection against Zika virus in diverse scenarios.

The inventive concept comprises a nucleic acid construct encoding the prM and E proteins of Zika virus, engineered to express a soluble, secreted E protein with enhanced stability and shelf life for high-security environments. Additionally, the vaccine is formulated to remain potent at elevated temperatures for disaster relief settings, and engineered to express a truncated E protein with enhanced thermal stability for extreme weather conditions. Furthermore, the vaccine can be adapted for rapid deployment in response to emerging outbreaks by expressing a self-amplifying RNA molecule, and for inducing immunity in individuals with compromised immune systems by eliciting a robust immune response.

The new claims provide a novel and non-obvious solution by adapting the recombinant measles virus expressing Zika virus prM and E proteins for specific, high-stakes environments. The inventive step lies in the tailored engineering of the vaccine components to address the unique challenges of each environment, ensuring effective protection against Zika virus in diverse scenarios.

Alternative embodiments of the inventive concept could include adapting the vaccine for use in other specialized environments, such as space exploration or high-altitude settings. Variations could also include using different viral vectors or expression systems to deliver the Zika virus prM and E proteins.

The adaptive Zika virus vaccine has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the areas of infectious disease prevention and pandemic response. Target markets include government agencies, non-profit organizations, and private companies involved in disaster relief, high-security operations, and extreme environment exploration.